OXURION

Welcome to the Brand page for “OXURION”, which is offered here for Biopharmaceutical preparations for use in the treatment of hypertension, strokes, cardiac diseases and vascular diseases; diagnostic medical reagents, chemicals preparations and biological materials all the foregoing being in the form of spatially defined arrays and solutions and reagents for medical laboratory use in diagnosting, monitoring, and predicting diseases and for measuring and predicting response to therapy of cardiac and vascular diseases; pharmaceutical preparations for use in the treatment of hypertension, strokes, cardiac diseases and vascular diseases; pharmaceutical substances and medicines for treatment or prevention of eye disorders and diseases and of ophthalmological disorders and diseases; pharmaceutical preparations and substances for the treatment or prevention of diabetes; medicines for treating or preventing diabetes; ophthalmic medicines and surgical fluids, ophthalmic pharmaceutical preparations; pharmaceutical eye drops;medical services; veterinary services; consultancy services, consultancy in the medical, veterinary and pharmaceutical treatment of patients in the fields of ophthalmology, diabetes and cardiovascular diseases; medical services, cardiac and vascular therapeutic, prognostic and diagnostic testing services;scientific and technological services, research and design relating thereto in the field of ophthalmology, in the field of diabetes and in the field of treatment of cardiovascular disease, cardiac disease and vascular disease; industrial analysis of the pharmaceutical preparations of others used for the treatment of ophthalmologic diseases, diabetes and cardiovascular diseases for quality control purposes; research services in the field of ophthalmology, diabetes and cardiovascular diseases; pharmaceutical and biopharmaceutical research and development; biopharmaceutical product evaluation; research in the field of treatment of cardiovascular disease, cardiac disease, and vascular disease; development of new treatments for pathologies in which vascular biology plays a critical role in the field of biopharmaceuticals;.

Its status is currently believed to be active. Its class is unavailable. “OXURION” is believed to be currently owned by “Oxurion NV”.